Clinical Trials
5 trialsNCT05119855 2026-02-05
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05556720 2025-10-03
BOOST-IC
Monash University
Phase 3 Active not recruiting
NCT04761822 2025-08-12
SARS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT04847050 2024-08-27
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05075538 2024-01-17
I-SPARC
Jules Bordet Institute
Phase 4 Terminated